Oncoinvent (ONCIN)

Ticker ONCIN Sector Health Care
Exchange Oslo Børs ISIN NO0013711713
No. of shares issued 4 478 412    

 

Largest shareholders

The above data is provided by Euronext and is obtained through an analysis of beneficial ownership and fund manager information provided in replies to disclosure of ownership notices issued to all custodians on the Oncoinvent VPS share register. Every reasonable effort has been made to verify the data, however neither Oncoinvent nor Euronext can guarantee the accuracy of the analysis.

Shareholder list including disclosure of nominee accounts

For a list of Oncoinvent’s shareholders as of 11 March 2026 including disclosure of nominee accounts, please contact IR@oncoinvent.com.

Account Manager
Oncoinvent’s shares are registered in Euronext Securities Oslo (previously known as VPS). DNB Bank acts as Oncoinvent’s account manager.

DNB Bank ASA
Securities services
Dronning Eufemias gate 30
N-0191 Oslo
NORWAY
Phone: +47 22 26 80 20
E-mail: kua@dnb.no

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close